Rebus Holdings Inc.
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
Rebus Holdings Inc. (RBSH) - Net Assets
Latest net assets as of June 2023: $-5.61 Million USD
Based on the latest financial reports, Rebus Holdings Inc. (RBSH) has net assets worth $-5.61 Million USD as of June 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.00K) and total liabilities ($5.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.61 Million |
| % of Total Assets | -62333.33% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -515.63% |
| Growth Volatility | 755.24 |
Rebus Holdings Inc. - Net Assets Trend (2007–2022)
This chart illustrates how Rebus Holdings Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Rebus Holdings Inc. (2007–2022)
The table below shows the annual net assets of Rebus Holdings Inc. from 2007 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-5.24 Million | -4.28% |
| 2021-12-31 | $-5.02 Million | +59.83% |
| 2020-12-31 | $-12.50 Million | -43.33% |
| 2019-12-31 | $-8.72 Million | +1.41% |
| 2018-12-31 | $-8.85 Million | 0.00% |
| 2017-12-31 | $-8.85 Million | -158.03% |
| 2016-12-31 | $-3.43 Million | -79.72% |
| 2015-12-31 | $-1.91 Million | -2067.01% |
| 2014-12-31 | $97.00K | -92.30% |
| 2013-12-31 | $1.26 Million | +273.08% |
| 2012-12-31 | $-728.00K | -123.84% |
| 2011-12-31 | $3.05 Million | +137.61% |
| 2010-12-31 | $1.29 Million | +2468.94% |
| 2009-12-31 | $-54.24K | -134.96% |
| 2008-12-31 | $155.18K | -62.77% |
| 2007-12-31 | $416.76K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rebus Holdings Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6385501500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | % |
| Other Components | $60.06 Million | % |
| Total Equity | $-5.24 Million | 100.00% |
Rebus Holdings Inc. Competitors by Market Cap
The table below lists competitors of Rebus Holdings Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KLN
WAR:KLN
|
$3.13K |
|
Medical Imaging Corp
PINK:MEDD
|
$3.13K |
|
Castlecap Capital Inc
V:CSTL-P
|
$3.13K |
|
MTL Cannabis Corp.
F:J4E
|
$3.13K |
|
BETA GLASS PLC
XNSA:BETAGLAS
|
$3.12K |
|
HuaAn Zhangjiang Everbright Park
SHG:508000
|
$3.12K |
|
Aptamer Group PLC
LSE:APTA
|
$3.12K |
|
Pakistan Aluminium Beverage Cans Ltd
KAR:PABC
|
$3.11K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rebus Holdings Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -5,022,000 to -5,237,000, a change of -215,000.
- Net loss of 1,253,000 reduced equity.
- Other factors increased equity by 1,038,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.25 Million | -23.93% |
| Other Changes | $1.04 Million | +19.82% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Rebus Holdings Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $46.31 | $0.00 | x |
| 2008-12-31 | $17.24 | $0.00 | x |
| 2009-12-31 | $-6.03 | $0.00 | x |
| 2010-12-31 | $128.50 | $0.00 | x |
| 2011-12-31 | $254.44 | $0.00 | x |
| 2012-12-31 | $-56.00 | $0.00 | x |
| 2013-12-31 | $78.75 | $0.00 | x |
| 2014-12-31 | $5.11 | $0.00 | x |
| 2015-12-31 | $-79.50 | $0.00 | x |
| 2016-12-31 | $-142.88 | $0.00 | x |
| 2017-12-31 | $-45844.56 | $0.00 | x |
| 2018-12-31 | $-45.84 | $0.00 | x |
| 2019-12-31 | $-2.79 | $0.00 | x |
| 2020-12-31 | $-0.02 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $-0.16 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rebus Holdings Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-653.69%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -165.85% | 0.00% | 0.00x | 1.42x | $-732.88K |
| 2008 | -2143.53% | 0.00% | 0.00x | 4.56x | $-3.34 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.13 Million |
| 2010 | -331.34% | 0.00% | 0.00x | 3.00x | $-4.39 Million |
| 2011 | -187.14% | 0.00% | 0.00x | 1.86x | $-6.02 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.85 Million |
| 2013 | -420.79% | 0.00% | 0.00x | 3.08x | $-5.43 Million |
| 2014 | -7210.31% | 0.00% | 0.00x | 27.10x | $-7.00 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.70 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.21 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.22 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.22 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-61.70K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.04 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $2.12 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-729.30K |
Industry Comparison
This section compares Rebus Holdings Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rebus Holdings Inc. (RBSH) | $-5.61 Million | -165.85% | N/A | $3.13K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |